Peptides DB
Research-centric peptide and protocol reference hub
Study 21 of 25Tirzepatide literatureColloids and surfaces. B, Biointerfaces · Animal study · Preclinical2026

A near-infrared light-triggered platform for on-demand drug release in bone repair.

A novel NIR-triggered scaffold shows promise for controlled drug release in bone repair, but human trials are needed to confirm clinical applicability.

Read at Colloids and surfaces. B, BiointerfacesAdd to compare

Where it sits

this study against the rest of the tirzepatide corpus
4
Preclinical · this one
15
Observational
1
Open-label
2
Randomised
3
Reviews

Summary and findings

The study developed a near-infrared (NIR) light-triggered platform for on-demand drug release in bone repair using a multifunctional biomimetic scaffold. The scaffold demonstrated dual-mode release behavior, good biocompatibility, and high antibacterial activity. The system showed accelerated drug release upon NIR irradiation and sustained release over 28 days without it.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Bacterial inhibition rate of 99%.Preclinical2026

Abstract

The authors’ words, as Colloids and surfaces. B, Biointerfaces supplied them

Three-dimensional (3D) of multifunctional bone scaffolds is currently a major research hotspot in the field of bone repair. Nevertheless, achieving on-demand modulation of scaffold performance remains a significant and unresolved challenge. In this study, the photothermal agent indocyanine green (ICG) was loaded into ZIF-8 and co-encapsulated with the osteogenic drug total flavonoids of Drynaria (TF) in thermosensitive PLGA microspheres to construct a NIR-triggered on-demand release module TF/ICG/ZIF-8@PLGA (TZP). This module was further integrated into a PLGA/β-TCP scaffold to develop a multifunctional biomimetic scaffold (TZP/PT).The system exhibited a dual-mode release behavior, showing sustained release over 28 days under non-NIR conditions and significantly accelerated release upon NIR irradiation, demonstrating an "on-off" switchable drug delivery profile. Biological evaluation demonstrated good biocompatibility, high antibacterial activity with a bacterial inhibition rate of 99%, and the formation of mineralized hydroxyapatite layers within 7 days, which can be attributed to combined osteogenic drug delivery and NIR-triggered photothermal (PTT) and photodynamic (PDT)-related effects.

Background

This study addresses the challenge of on-demand modulation of bone scaffold performance, a significant issue in bone repair research. Previous efforts have focused on developing multifunctional scaffolds, but achieving controlled drug release remains difficult. This research is important as it explores a novel NIR-triggered platform for drug release, potentially enhancing scaffold performance in bone repair.

Methods

The study utilized a photothermal agent, indocyanine green (ICG), loaded into ZIF-8 and co-encapsulated with total flavonoids of Drynaria (TF) in thermosensitive PLGA microspheres. This was integrated into a PLGA/β-TCP scaffold to create a multifunctional biomimetic scaffold. The system's release behavior was tested under NIR and non-NIR conditions, and its biological properties were evaluated for biocompatibility and antibacterial activity.

Results

The primary observation was the dual-mode release behavior of the scaffold, with sustained release over 28 days without NIR and accelerated release with NIR irradiation. The scaffold demonstrated a bacterial inhibition rate of 99% and facilitated the formation of mineralized hydroxyapatite layers within 7 days, indicating effective drug delivery and photothermal and photodynamic effects.

Interpretation

The study's findings suggest that the NIR-triggered platform could offer a novel method for controlled drug release in bone repair. However, the clinical significance is unclear due to the absence of human trials. The high antibacterial activity and mineralization observed are promising, but the lack of long-term data and human applicability limits the immediate clinical relevance.

Key findings

  • Sustained release over 28 days under non-NIR conditions.
  • Accelerated release upon NIR irradiation.
  • Bacterial inhibition rate of 99%.
  • Formation of mineralized hydroxyapatite layers within 7 days.

Limitations

  • Preclinical model, no human data.
  • Long-term effects untested.
  • Clinical applicability unknown.

Elsewhere in the Tirzepatide corpus

BDual GIP/GLP-1 Receptor Agonist Versus Selective GLP-1 Receptor Agonist in Patients Undergoing Primary Total Knee or Hip Arthroplastybiorxiv-preprint · At 2 years, tirzepatide exposure was associated with lower odds of mechanical complications (OR 0.64, 95% CI 0.42 to 0.96).HumanCTirzepatide preserves hematopoietic stem and progenitor cycling while remodeling inflammatory monocytes in obese micebiorxiv-preprint · Not reported in abstract.AnimalDThe GLP-1 Nutritional Paradox: A Structured Review with Novel Quantitative Frameworks for Sarcopenic Risk and Micronutrient Adequacy in GLP-1 Receptor Agonist Pharmacotherapybiorxiv-preprint · Mean body-weight reduction of 20.9% with tirzepatide in phase 3 trials.reviewBWeight Loss With Microdose Tirzepatide: Real-World Outcomes in Patients Initiating Treatment Below 2.5 mg Weeklybiorxiv-preprint · Mean body-weight loss was 6.10% (95% CI 4.60-7.60; n=8) in the 60-89-day window at a median 65.5 days.HumanDFrom adiposity to multisystem morbidity: the case for weight loss as disease modification.The lancet. Diabetes & endocrinology · 2026AInsights from a double-blind, randomized, direct-to-participant intervention trial for Long COVIDbiorxiv-preprint · 2026 · 1,058 participants enrolled in 73 days.Human